Shaniqua J. Anum, Julie Kanter/ scholars.uab.edu
Aug 23, 2026, 14:10
Intravenous Arginine Fails to Reduce Acute Sickle Cell Pain – JAMA
JAMA shared a post on LinkedIn about a recent article by Shaniqua J. Anum and Julie Kanter, adding:
”Acute pain episodes in Sickle Cell Disease remain a leading cause of emergency department visits and hospitalization, yet treatment still relies largely on opioids, nonsteroidal anti-inflammatory drugs, and intravenous fluids.
The STArT trial of intravenous Arginine found no overall benefit vs placebo, and heterogeneity in acute pain mechanisms and trial end points may have limited detection of a vascular-targeted treatment effect.”
Title: Arginine Treatment and Sickle Cell Disease Pain — A Great STArT, but a Hard End Point
Authors: Shaniqua J. Anum, Julie Kanter
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia
-
Aug 23, 2026, 10:10Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:03Balaji Balagani: Major Causes of Sudden Cardiac Death in Children
-
Aug 23, 2026, 16:02Bartosz Hudzik: What’s Hot at ESC Congress 2026
-
Aug 23, 2026, 16:01Jim Hoffman: NETs in STEMI and Their Association With PCI and Antithrombotic Treatments
-
Aug 23, 2026, 16:01Luis Oliverio Ambriz Garcia: Key Insights Into Myeloproliferative Neoplasms From the 2026 NEJM Review
-
Aug 23, 2026, 15:58Howard Smith: Automated MR Imaging Aids New Stroke Therapy Development
-
Aug 23, 2026, 15:58Nilesh Jethwa: Top Reported Adverse Reactions to Apixaban